| Literature DB >> 25220689 |
S Kinra1, M Johnson2, B Kulkarni3, K V Rameshwar Sarma4, Y Ben-Shlomo5, G D Smith6.
Abstract
OBJECTIVES: This study examined association between socio-economic position and cardiovascular risk factors in adolescents to investigate whether childhood socio-economic position is a risk factor for future cardiovascular disease, independently of adult behaviours. STUDY DESIGN AND METHODS: Participants (n = 1128, 46% girls, aged 13-18 years) were members of a birth cohort (Andhra Pradesh Children and Parents Study or APCAPS) established to investigate long-term effects of a pregnancy and childhood nutritional supplementation trial conducted in 29 villages near Hyderabad in South India. Cross-sectional associations between socio-economic position and cardiovascular risk factors were examined using linear regression models.Entities:
Keywords: Adolescents; Cardiovascular risk; Cohort studies; Fat mass index; Indian; Socio-economic position
Mesh:
Substances:
Year: 2014 PMID: 25220689 PMCID: PMC4211329 DOI: 10.1016/j.puhe.2014.06.005
Source DB: PubMed Journal: Public Health ISSN: 0033-3506 Impact factor: 2.427
Participant characteristics by Standard of Living Index (SLI), ÁPCAPS follow-up, 2003–05.
| Boys ( | Girls ( | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Low SLI ( | Middle SLI ( | High SLI ( | Low SLI ( | Middle SLI ( | High SLI ( | |||||
| Age (years) | 607 | 15.9 (0.9) | 15.9 (0.9) | 15.9 (0.8) | 0.967 | 521 | 15.7 (0.9) | 15.8 (0.9) | 15.8 (1.0) | 0.855 |
| Pubertal stage ( | 604 | 0.508 | 517 | 0.880 | ||||||
| Early puberty | 171 | 38 (23.5) | 87 (31.0) | 46 (28.6) | 0 | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Middle puberty | 322 | 94 (58.0) | 145 (51.6) | 83 (51.6) | 43 | 4 (8.3) | 22 (8.9) | 17 (7.7) | ||
| Late puberty | 111 | 30 (18.5) | 49 (17.4) | 32 (19.9) | 204 | 17 (35.4) | 94 (38.1) | 93 (41.9) | ||
| Postpuberty | 0 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 270 | 27 (56.3) | 131 (53.0) | 112 (50.5) | ||
| Height (mm) | 604 | 1580.5 (81.5) | 1579.3 (86.7) | 1613.1 (82.7) | <0.001 | 516 | 1495.0 (58.8) | 1516.4 (55.4) | 1517.3 (58.1) | 0.040 |
| Body mass index (kg/m2) | 604 | 16.5 (1.8) | 16.5 (1.8) | 17.2 (2.6) | <0.001** | 516 | 17.8 (2.2) | 17.7 (1.8) | 18.0 (2.6) | 0.254** |
| Fat mass index (kg/m2) | 604 | 1.5 (0.5) | 1.6 (0.6) | 1.8 (1.0) | <0.001** | 516 | 3.7 (1.0) | 3.7 (0.9) | 3.8 (1.3) | 0.226** |
| Central-peripheral skinfold ratio | 604 | 1.6 (0.2) | 1.5 (0.2) | 1.5 (0.2) | 0.002 | 516 | 1.5 (0.3) | 1.4 (0.2) | 1.4 (0.2) | 0.033 |
| Systolic blood pressure (mmHg) | 603 | 109.7 (11.1) | 110.2 (10.7) | 112.2 (10.9) | 0.080 | 515 | 107.5 (8.3) | 107.5 (9.3) | 107.2 (9.2) | 0.917 |
| Diastolic blood pressure (mmHg) | 603 | 61.4 (6.8) | 61.7 (6.5) | 63.8 (6.4) | 0.001 | 515 | 63.0 (5.7) | 62.6 (7.0) | 62.7 (6.0) | 0.924 |
| Augmentation index (%) | 486 | 5.1 (10.4) | 3.8 (9.8) | 1.8 (10.9) | 0.035 | 376 | 6.8 (12.3) | 3.9 (11.1) | 4.8 (9.9) | 0.365 |
| Total cholesterol (mmol/l) | 567 | 3.2 (0.6) | 3.3 (0.7) | 3.3 (0.6) | 0.769 | 483 | 3.5 (0.7) | 3.6 (0.7) | 3.7 (0.7) | 0.040 |
| LDL cholesterol (mmol/l) | 567 | 1.9 (0.5) | 1.9 (0.6) | 2.0 (0.5) | 0.577 | 483 | 2.1 (0.7) | 2.2 (0.6) | 2.2 (0.6) | 0.247 |
| HDL cholesterol (mmol/l) | 567 | 1.0 (0.2) | 1.0 (0.2) | 1.0 (0.2) | 0.146 | 483 | 0.9 (0.3) | 1.0 (0.2) | 1.0 (0.2) | 0.093 |
| Triglycerides | 567 | 0.8 (1.4) | 0.8 (1.4) | 0.7 (1.4) | 0.036 | 483 | 0.9 (1.5) | 0.9 (1.4) | 0.9 (1.5) | 0.305 |
| Glucose (mmol/l) | 543 | 4.7 (0.7) | 4.7 (0.6) | 4.7 (0.6) | 0.828 | 465 | 4.7 (0.6) | 4.8 (0.8) | 4.6 (0.6) | 0.027** |
| Insulin | 543 | 16.4 (1.7) | 15.2 (1.8) | 17.9 (1.8) | 0.020 | 465 | 16.6 (1.8) | 16.7 (1.8) | 18.1 (1.7) | 0.275 |
| HOMA score | 541 | 3.4 (1.7) | 3.1 (1.8) | 3.7 (1.8) | 0.022 | 462 | 3.4 (1.8) | 3.4 (1.9) | 3.7 (1.7) | 0.474 |
LDL: low density lipoprotein; HDL: high density lipoprotein; HOMA: homoeostasis modal assessment.
Unless stated otherwise, values are means (standard deviations).
* P-values are based on one-way analysis of variance (ANOVA) and Chi-squared tests with appropriate degrees of freedom.
** P-values are based on weighted ANOVAs to account for heterogeneity of variances.
Geometric means and geometric standard deviations as factor on logarithmic scale.
Association between Standard of Living Index and cardiovascular risk among participants of the ÁPCAPS follow-up, 2003–05.
| Model 1 | Model 2 | Model 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 95% CI | 95% CI | 95% CI | |||||||
| Fat mass index (kg/m2) | 0.15 | 0.05 to 0.25 | 0.01 | 0.13 | 0.04 to 0.23 | 0.01 | 0.15 | 0.05 to 0.25 | 0.01 |
| Central-peripheral skinfold ratio | −0.04 | −0.06 to −0.01 | 0.01 | −0.05 | −0.07 to −0.02 | <0.01 | −0.05 | −0.07 to −0.03 | <0.01 |
| Systolic blood pressure (mmHg) | 0.55 | −0.23 to 1.33 | 0.16 | 0.09 | −0.61 to 0.78 | 0.80 | 0.15 | −0.58 to 0.87 | 0.68 |
| Diastolic blood pressure (mmHg) | 0.54 | 0.07 to 1.00 | 0.03 | 0.40 | −0.07 to 0.87 | 0.09 | 0.38 | −0.08 to 0.84 | 0.10 |
| Augmentation index (%) | −1.21 | −2.36 to −0.06 | 0.04 | −0.72 | −1.84 to 0.40 | 0.20 | −0.63 | −1.72 to 0.45 | 0.24 |
| Total cholesterol (mmol/l) | 0.06 | −0.01 to 0.13 | 0.06 | 0.07 | 0.01 to 0.13 | 0.04 | 0.05 | −0.01 to 0.11 | 0.10 |
| LDL cholesterol (mmol/l) | 0.05 | −0.01 to 0.10 | 0.09 | 0.05 | −0.01 to 0.11 | 0.08 | 0.03 | −0.02 to 0.08 | 0.20 |
| HDL cholesterol (mmol/l) | 0.02 | −0.01 to 0.04 | 0.06 | 0.02 | 0.01 to 0.04 | 0.04 | 0.02 | −0.01 to 0.04 | 0.06 |
| Triglycerides | −0.05 | −0.09 to −0.01 | 0.02 | −0.04 | −0.09 to −0.01 | 0.03 | −0.04 | −0.08 to −0.01 | 0.02 |
| Triglycerides | −0.04 | −0.02 to 0.11 | 0.17 | 0.05 | −0.02 to 0.11 | 0.14 | −0.05 | −0.02 to 0.11 | 0.17 |
| Glucose (mmol/l) | −0.04 | −0.12 to 0.04 | 0.29 | −0.04 | −0.12 to 0.04 | 0.29 | −0.03 | −0.10 to 0.04 | 0.35 |
| Insulin | 0.06 | 0.01 to 0.11 | 0.05 | 0.05 | −0.01 to 0.10 | 0.10 | 0.05 | −0.01 to 0.10 | 0.07 |
| HOMA score | 0.05 | −0.01 to 0.11 | 0.09 | 0.04 | −0.02 to 0.10 | 0.16 | 0.05 | −0.01 to 0.11 | 0.11 |
LDL: low density lipoprotein; HDL: high density lipoprotein; HOMA: homoeostasis modal assessment.
β coeff: β coefficients are the mean differences across categories of the Standard of Living Index (i.e. average difference between the middle SLI – low SLI and high SLI– middle SLI categories). Positive difference indicates a higher value in the higher Standard of Living Index category.
Model 1: adjusted for age, gender (except triglyceride models), nutritional supplementation, room temperature (blood pressure only) and heart rate (augmentation index only).
Model 2: adjusted for variables in model 1 + height.
Model 3: adjusted for variables in model 2 + pubertal stage, fat mass index and central-peripheral skinfold ratio.
Sample size: n = 1120 for fat mass index and central-peripheral skin fold ratio; n = 1118 for systolic and diastolic blood pressure; n = 862 for augmentation index; n = 1050 for total cholesterol, LDL cholesterol and HDL cholesterol; n = 567 for triglycerides in boys and n = 483 for triglycerides in girls; n = 1008 for glucose and insulin; and n = 1003 for HOMA score.
Not adjusted for fat mass index.
Not adjusted for central-peripheral skinfold ratio.
Differences between means are on log scale. On original scale these equate to (for model 1): triglycerides in boys 0.95 (0.91–0.99), triglycerides in girls 1.04 (0.98–1.12), insulin 1.06 (1.00–1.12) and HOMA score 1.05 (0.99–1.12).
There was no strong evidence of interaction between Standard of Living Index and sex for any of the outcome measures except triglycerides (Pinteraction = 0.008), for which data are presented separately for boys and girls.